Conatus Pharmaceuticals, a US-based biotechnology company backed by investors including Roche Finance Ltd, part of the Switzerland-based healthcare company Roche, has filed for an initial public offering (IPO) on Nasdaq.
Roche Finance holds a 6.7% stake in Conatus; other investors include investment firms Aberdare Ventures, Advent Venture Capital, Gilde Healthcare, AgeChem Venture Fund, Bay City Capital and MPM Capital.
Stifel and Piper Jaffray & Co. are acting as joint book-running managers for the offering. JMP Securities LLC is acting as co-lead manager and SunTrust Robinson Humphrey, Inc. is acting as co-manager for the offering.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.